The Conversation (0)
Theralase Shares Latest Research at Photodynamic Association Meeting
Jun. 15, 2017 08:34AM PST
Biotech Investing
Theralase Technologies released new research on phosphorescent photosensitizers was presented at this year’s International Photodynamic Association World Congress.
Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) released new research on phosphorescent photosensitizers was presented at this year’s International Photodynamic Association World Congress.
As quoted in the press release:
Angelika Rueck, Ph.D, University of Ulm, presented, “New phosphorescent Photo Sensitizers (“PS“) to follow up PDT response by Fluorescence Lifetime Imaging (“FLIM“) and PS Phosphorescence Lifetime Imaging (“PLIM“).”
Dr. Rueck presented how the Theralase patented PDC, TLD-1433, has demonstrated pre-clinically that:
- It is able to localize to the mitochondria of T-24 human bladder cancer cells and not the nucleus (Effective way to kill cancer cells without nuclear damage)
- Under simultaneous FLIM and PLIM activation the cell’s metabolism and oxygenation during PDT can be measured (By measuring oxygenation levels during PDT, the efficacy of PDT treatment can be optimized)
TLD-1433 PLIM and NADH FLIM can determine oxygenation and cellular metabolism during PDT and hence optimize efficacy of the treatment for various cancer cell types.
Angelika Ruelck, Ph.D., stated that, “FLIM/PLIM allows deep insight into the light induced mechanisms during PDT, allowing Theralase the opportunity to overcome the difficulty of treating under hypoxic (low oxygen) conditions or hypoxic tumour areas, common to cancer cells. The combination of PLIM with PDT treatment planning using TLD-1433, opens new avenues towards increasing patient outcomes during PDT treatment.”
Roger Dumoulin-White, President and CEO of Theralase, stated that, “Theralase is delighted that Dr. Rueck presented the latest research on phosphorescent photosensitizers to such a respected group of international researchers and clinicians at the 16th IPA World Congress. This research will allow Theralase the ability to successfully commercialize this next generation PDT technology for NMIBC and various other cancers.”
Click here to read the full press release.
Source: www.accesswire.com